Edition:
India

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

6,422JPY
11:30am IST
Change (% chg)

¥31 (+0.49%)
Prev Close
¥6,391
Open
¥6,449
Day's High
¥6,465
Day's Low
¥6,400
Volume
2,139,700
Avg. Vol
2,013,220
52-wk High
¥6,693
52-wk Low
¥4,664

Chart for

About

Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases,... (more)

Overall

Beta: 0.71
Market Cap(Mil.): ¥4,891,410.00
Shares Outstanding(Mil.): 790.85
Dividend: 90.00
Yield (%): 2.91

Financials

  Industry Sector
P/E (TTM): -- 31.11 16.44
EPS (TTM): -- -- --
ROI: -- 14.85 10.61
ROE: -- 16.31 14.21

BRIEF-Arcturus Announces Expansion Of Collaboration With Takeda

* ARCTURUS THERAPEUTICS ANNOUNCES EXPANSION OF COLLABORATION WITH TAKEDA PHARMACEUTICALS TO DEVELOP RNA-BASED THERAPEUTICS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH) AND OTHER GI DISORDERS

17 Jan 2018

BRIEF-Takeda And Denali Therapeutics Collaborate To Develop Therapies For Neurodegenerative Diseases

* TAKEDA AND DENALI THERAPEUTICS COLLABORATE TO DEVELOP AND COMMERCIALIZE THERAPIES FOR NEURODEGENERATIVE DISEASES

05 Jan 2018

Japan's Takeda to acquire TiGenix for $630 mln

TOKYO, Jan 5 Japan's Takeda Pharmaceutical Co said on Friday it has agreed to buy Belgian biotech group TiGenix NV for 520 million euros ($628 million).

05 Jan 2018

Amgen's Kyprolis improves overall survival in blood cancer patients

Amgen Inc said on Monday a final analysis of late-stage trial data showed that its Kyprolis combined with two other drugs helped blood cancer patients live longer.

12 Dec 2017

UPDATE 1-Amgen's Kyprolis improves overall survival in blood cancer patients

Dec 11 Amgen Inc said on Monday a final analysis of late-stage trial data showed that its Kyprolis combined with two other drugs helped blood cancer patients live longer.

12 Dec 2017

BRIEF-Takeda Pharma Announces Research Collaboration In ALS With Montreal Neurological Institute​

* TAKEDA PHARMACEUTICAL ANNOUNCES RESEARCH COLLABORATION IN ALS WITH MONTREAL NEUROLOGICAL INSTITUTE​

04 Dec 2017

BRIEF-Takeda Pharmaceutical unit signs agreement for sale of properties worth 49.5 bln yen

* Says its wholly owned subsidiary Takeda Pharmaceutical Real Estate Company has signed an agreement with Takashimaya Company Limited for the sale of properties

01 Dec 2017

BRIEF-U.S. FDA provides new drug safety communication on Takeda's gout drug

* U.S. FDA says preliminary results from a safety clinical trial show increased risk of heart-related death with Febuxostat (Uloric) versus Allopurinol

16 Nov 2017

BRIEF-TAKEDA RECEIVES POSITIVE CHMP OPINION FOR ADCETRIS FOR CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA

* TAKEDA RECEIVES POSITIVE CHMP OPINION FOR ADCETRIS® (BRENTUXIMAB VEDOTIN) FOR CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA

14 Nov 2017

Takeda takes on Sanofi with new global dengue vaccine data

Takeda Pharmaceutical's experimental dengue vaccine has produced promising long-term results in clinical tests, boosting the Japanese company's global hopes for a product that will take on Sanofi's Dengvaxia.

07 Nov 2017

Earnings vs. Estimates